BIOPHYTIS (EPA:ALBPS) - Biophytis Announces Three Oral and One Poster Presentations at the 2019 International Conference on Frailty and Sarcopenia Research
Directive transparence : information réglementée Autres communiqués
18/02/2019 07:00
Cliquez ici pour télécharger le pdf
Press release
Biophytis Announces Three Oral and One Poster Presentations at the 2019
International Conference on Frailty and Sarcopenia Research
ICFSR 2019 will take place Feb. 20-22, 2019 in Miami Beach, FL
Paris (France), Feb. 18, 2019, 7:00am CET - Biophytis SA (Euronext Growth
Paris: ALBPS), a clinical-stage biotechnology company focused on the
development of novel therapeutics for age-related diseases, today announced
upcoming oral and poster presentations at the 2019 International Conference on
Frailty and Sarcopenia Research (ICFSR 2019) being held from February 20 to 22,
2019 in Miami Beach, FL. The Company will present details of its lead clinical
drug candidate, Sarconeos (BIO101), including its history and unique mechanism-
of-action that targets the MAS receptor for the preservation of muscle function
in muscle wasting disorders. Additionally, the Company will present the
clinical trial design of its ongoing SARA Phase 2 study of Sarconeos (BIO101)
in sarcopenia.
Stanislas Veillet, Ph.D., Chief Executive Officer of Biophytis said, "We are
pleased to have been selected for three oral presentations and a poster at
ICFSR 2019. We look forward to sharing the potential of Sarconeos (BIO101) for
the treatment of sarcopenia and other muscular dystrophies with leading
international clinicians and scientists from industry and academia. We believe
Sarconeos (BIO101) is one of the most advanced drug candidates in clinical
development for the treatment of sarcopenia, a severe geriatric muscle wasting
condition with no currently approved medication."
Details of the presentations are as follows:
Title: Sarconeos (API BIO101) targets Mas receptor within the
protective arm of the renin angiotensin system and proves
efficacy in various models of muscle wasting.
Presenter: Pierre Dilda, Ph.D.
Date/Time: Wednesday, Feb. 20, 2019 / 5:30 pm EST
Additional Info: Oral Communication 10
Title: Insect Steroid Hormones as Human Medicine: Application to
Sarcopenia and Muscle Dystrophies.
Presenter: Stanislas Veillet, Ph.D.
Date/Time: Thursday, Feb. 21, 2019 / 12:25 pm EST
Additional Info: Oral Presentation at the Lunch Industry Symposium hosted by
Biophytis
Title: Designing a clinical program for BIO101, a Mas receptor
activator to target age-related sarcopenia.
Presenter: Waly Dioh, Ph.D.
Date/Time: Thursday, Feb. 21 2019 / 12:25 pm EST
Additional Info: Oral Presentation at the Lunch Industry Symposium hosted by
Biophytis
Title: Evaluation of safety and efficacy of BIO101, a new
investigational drug for sarcopenia: a double-blind, placebo
controlled, randomized clinical trial.
Presenter: Waly Dioh, Ph.D.
Date/Time: Thursday, Feb. 21, 2019
Additional Info: Poster: Clinical Trials and Therapeutics P78
About Biophytis
Biophytis is a clinical-stage biotechnology company focused on the development
of novel therapeutics that slow the degenerative processes and improve
functional outcomes for patients suffering from age-related diseases. Our
therapeutic approach targets key biological resilience pathways that can
protect against and counteract the effects of the multiple biological stresses
that lead to age-related diseases. Our lead drug candidate, Sarconeos (BIO101),
is for the treatment of neuromuscular diseases, including sarcopenia and
Duchenne muscular dystrophy. Our second drug candidate, Macuneos (BIO201), is
for the treatment of retinopathies, including dry age-related macular
degeneration (AMD) and Stargardt disease. Biophytis is based in Paris, France
and in Cambridge, Massachusetts. For more information, please visit
www.biophytis.com.
BIOPHYTIS is listed on the Euronext Growth market of Euronext Paris (ALBPS;
ISIN: FR0012816825).
Follow us on Twitter @biophytis
BIOPHYTIS is eligible for the SMEs scheme
Disclaimer
This press release contains certain forward-looking statements. Although the
Company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the Company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Listing Prospectus upon the
admission of Company's shares for trading on the regulated market Euronext
Growth of Euronext Paris filed with the AMF, which is available on the AMF
website (www.amf-france.org) or at www.biophytis.com.
This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Biophytis in any country. Items in this press release may contain forward-
looking statements involving risks and uncertainties. The Company's actual
results could differ substantially from those anticipated in these statements
owing to various risk factors which are described in the Company's prospectus.
This press release has been prepared in both French and English. In the event
of any differences between the two texts, the French language version shall
prevail.
Biophytis
Daniel SCHNEIDERMAN
Chief Financial Officer
dan.schneiderman@biophytis.com
Tel: +1 (646) 479-8060
U.S. Media Contact
LifeSci Public Relations
Cherilyn CECCHINI, M.D.
ccecchini@lifescipublicrelations.com
Tel: +1 (646) 876-5196
Europe Media Contact
Citigate Dewe Rogerson
Laurence BAULT / Antoine DENRY
laurence.bault@citigatedewerogerson.com
antoine.denry@citigatedewerogerson.com
Tel: +33 (0)1 53 32 84 78
Mob: +33(0)6 64 12 53 61